Posts Tagged ‘award winning fish oil’

Omega 3 EPA the key omega3 to tackle obesity and type 2 diabetes

Saturday, October 8th, 2011

A major risk factor for cardiovascular disease, type 2 diabetes
and other pro inflammatory life-threatening conditions is the current obesity epidemic which is endemic in developed nations such as United States , United Kingdom , UAE where it’s fueled in large part by excessive consumption of a fat-rich “Western style diet.” The main issue is the increase consumption of saturated fats which are pro inflammatory ie animal fats , sunflower oil , corn oil etc Animal-derived saturated fats like lard and butter are strongly linked to adverse health effects, but unsaturated and polyunsaturated fats from plants and cold-water fish like salmon and mackerel are not. In fact, eating oily fish which is rich in omega3 especially EPA produces beneficial health effects and can reduce the risk of cardiovascular disease and diabetes
For biomedical investigators, the enduring question has been why saturated and unsaturated fatty acids produce such diametrically opposed health effects. Now, in a paper published in the Sept. 30 issue of the journal Cell, researchers at the University of California San Diego School of Medicine and colleagues offer an explanation, and a framework that could lead to dietary supplements designed to treat obesity at the molecular level.

“These findings not only explain the long-standing enigma regarding the differential health effects of saturated and unsaturated fatty acids,” said senior author Michael Karin, PhD, Distinguished Professor of Pharmacology in UC San Diego’s Laboratory of Gene Regulation and Signal Transduction, “they also provide improved tools and a mechanistic framework for the potential development of dietary supplements to treat obesity, estimated to be worth billions of dollars per year.”

Senior author Karin, first author Ryan G. Holzer, PhD, formerly a graduate student in Karin’s lab and now at the Mayo Clinic, and colleagues began with the observation that saturated fatty acids, such as palmitic acid, are potent activators of Jun kinases (JNK), key regulatory molecules implicated in the development of type 2 diabetes, insulin resistance, obesity and atherosclerosis. However, unsaturated fatty acids such as palmitoleic acid (POA) and eicosapentaenoic acid (EPA) not only do not activate JNK, but actually block JNK activation by palmitic acid.

Palmitic acid and POA differ in molecular structure by the presence of a single unsaturated bond (the absence of two hydrogen atoms) in POA. Cellular membrane fluidity is decreased upon incorporation of saturated fatty acids, which possess rigid hydrocarbon tails, but increased by the incorporation of unsaturated fatty acids with “bent” hydrocarbon tails.

Postulating that the membrane is the only cellular structure that can discriminate between all of these fatty acids, the scientists searched for membrane-associated protein kinases that could account for the differential effects on JNK activity. They ultimately identified c-Src, a membrane-associated tyrosine kinase, as the molecule responsible for activation of JNK by palmitic acid and other saturated fatty acids. They also discovered that saturated fatty acids “push” c-Src into membrane sub-domains of reduced fluidity and increased rigidity, where it accumulates in an activated form that eventually leads to JNK activation.

By contrast, POA and EPA prevent these changes in the membrane distribution of c-Src and — by blocking c-Src aggregation — they inhibit its activation by saturated fatty acids.

Most of the research was conducted using cultured cells (fibroblasts) treated with individual or combined fatty acids, but the scientists also fed mice a high-fat diet (in which 60 percent of the calories were fat-derived) and reported similar c-Src accumulation within membrane subdomains of increased rigidity and JNK activation.

Currently, polyunsaturated fatty acids, such as EPA and structurally-related omega-3 fatty acids are used in the treatment of hyperlipidemia (high blood cholesterol levels) and may be effective in the treatment or prevention of type 2 diabetes. Karin said understanding how EPA works could lead to the identification of even more potent EPA-like molecules.

Funding for this research came from the National Institutes of Health, the Superfund Basic Research Program and the American Diabetes Association.

Co-authors of the paper are Eek-Joong Park, Ning Li, Helen Tran, Monica Chen and Crystal Choi, Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, UC San Diego; and Giovanni Solinas, Laboratory of Metabolic Stress Biology, Department of Medicine, Physiology, University of Fribourg, Switzerlan

Consumption Of Omega-3 essential Fatty acid fish oils Decrease Homocysteine Levels In Diabetic Patients

Friday, July 29th, 2011

Consumption Of Omega-3 FAs Decrease Homocysteine Levels In Diabetic Patients
Pooya S, Jalali MD, Jazayery AD, et al. The efficacy of omega-3 fatty acid supplementation on plasma homocysteine and malondialdehyde levels of type 2 diabetic patients. Nutr Metab Cardiovasc Dis. 2009;18.
BACKGROUND AND AIMS: Cardiovascular diseases are the major cause of mortality among diabetic patients. The concentration of malondialdehyde (MDA) and homocysteine is believed to play a role in cardiovascular diseases. Omega-3 fatty acid supplementation could be effective in some diabetes complications and in the control of the glycemic index. However, it may increase lipid peroxidation. The objective of this study was to determine the effect of omega-3 fatty acids on the concentration of homocysteine and MDA in diabetic patients.

METHODS AND RESULTS: A randomized double-blind, placebo-controlled clinical trial was conducted on 81 patients with type 2 diabetes. The patients were randomly assigned to either the treatment or control groups. Each subject received three capsules of omega-3 fatty acids or a placebo every day for a period of 2months. The two groups were similar in terms of body mass index and food intake. At the beginning of the study and after 2months of supplementation their levels of HbA(1)c, homocysteine, MDA, C-reactive protein (CRP), total cholesterol, LDL-cholesterol and fasting blood sugar (FBS) were determined. Due to omega-3 fatty acid supplementation, homocysteine was changed significantly in both treatment and control groups up to -3.10mumol/L and 0.10mumol/L respectively, and HbA(1)c decreased by 0.75% in the treatment group and increased by 0.26% in the control group. However, the changes in fasting blood sugar (FBS), malondialdehyde (MDA), C-reactive protein (CRP), total cholesterol and LDL-cholesterol levels were not significant.

CONCLUSION: The consumption of omega-3 fatty acid supplements (3g/day) for 2months decreases the levels of homocysteine in diabetic patients with no change in FBS, MDA and CRP levels.

Great Britain Flag
Made in the UK - Take Omega 3 Suspendisse lacinia ultricies justo, at ultricies nisi tempus ac. Cras sed vehicula metus. Phasellus...